Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PARAPLATIN vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
Ovarian carcinoma: treatment of advanced ovarian carcinoma in combination with other chemotherapy agents,Non-small cell lung cancer: treatment of advanced NSCLC in combination with other agents,Off-label: head and neck cancer, bladder cancer, endometrial cancer, testicular cancer, small cell lung cancer
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/m L/min IV every 3-4 weeks using Calvert formula.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal elimination half-life: 2.6-5.1 hours (initial phase), 22-52 hours (terminal phase) for total platinum; 1.3-2.1 hours for ultrafilterable platinum. Clinically, the terminal half-life reflects slow release of protein-bound platinum.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Carboplatin is minimally metabolized in the liver; the majority of the drug is eliminated unchanged by renal excretion via glomerular filtration and tubular secretion. It is not extensively metabolized by cytochrome P450 enzymes.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Renal excretion: ~70-90% of platinum is excreted in urine within 24 hours, primarily as unchanged drug. Fecal excretion: <6%. Biliary excretion: minimal.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Protein binding: ~90% of circulating platinum is irreversibly bound to plasma proteins (primarily albumin) within 4 hours of infusion; only free drug is pharmacologically active.
47% bound to human plasma proteins, primarily albumin.
Volume of distribution: 10-16 L/kg (total platinum), 0.3-0.5 L/kg (ultrafilterable platinum). High Vd indicates extensive tissue distribution, including into tumors.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
IV administration only; oral bioavailability is negligible (<2%) due to poor absorption and rapid degradation in GI tract.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
Creatinine clearance (Cr Cl) 41-59 m L/min: 250 mg/m2 IV every 3-4 weeks; Cr Cl 16-40 m L/min: 200 mg/m2 IV every 3-4 weeks; Cr Cl <15 m L/min: not recommended. Alternatively, AUC dosing: Cr Cl 41-59 m L/min: AUC 4; Cr Cl 16-40 m L/min: AUC 3; Cr Cl <15 m L/min: not recommended.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No specific Child-Pugh based modifications established; use caution in severe hepatic impairment; baseline dose reduction to 200-250 mg/m2 recommended in patients with bilirubin >1.5 mg/d L or transaminases >2x upper limit of normal.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
300-600 mg/m2 IV every 3-4 weeks; alternatively, 90-150 mg/m2 IV weekly for 4 weeks then 2-week rest. Adjust for renal function using Calvert formula with pediatric GFR estimation.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment solely for age; calculate dose based on GFR using Calvert formula; monitor for increased myelosuppression and neurotoxicity; consider starting at lower AUC (4-5) in patients with decreased renal function.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
Carboplatin should be administered under the supervision of a physician experienced in cancer chemotherapy. Myelosuppression is dose-dependent and may be severe, with bone marrow suppression requiring close monitoring. Anaphylactic reactions have been reported and may be fatal. Use caution in patients with prior hypersensitivity to platinum compounds.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Bone marrow suppression (thrombocytopenia, neutropenia, anemia) is dose-limiting; monitor blood counts. Nephrotoxicity may occur, especially in patients with renal impairment; assess renal function before and during therapy. Neurotoxicity (peripheral neuropathy) is less common than with cisplatin but may occur. Ototoxicity risk increases with higher cumulative doses. Anaphylactic reactions can occur. Hemolytic uremic syndrome has been reported. Use caution in patients with prior platinum hypersensitivity.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
History of severe allergic reactions to carboplatin or other platinum-containing compounds; severe bone marrow suppression; significant bleeding disorders; severe renal impairment (creatinine clearance < 30 m L/min) unless benefit outweighs risk.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No significant food interactions. Avoid grapefruit and grapefruit juice if patient is on concurrent CYP3A4-metabolized drugs (e.g., aprepitant).
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Pregnancy Category D. First trimester: High risk of teratogenicity; embryotoxicity, fetal malformations (neural tube, skeletal, cardiovascular). Second and third trimesters: Risk of fetal growth restriction, prematurity, low birth weight, neonatal myelosuppression, and long-term developmental effects.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
Excreted in human milk; no M/P ratio available. Risk of severe neonatal adverse effects; contraindicated during breastfeeding. Discontinue drug or nursing.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No established specific dose adjustments in pregnancy; physiological changes (increased plasma volume, enhanced renal clearance) may reduce systemic exposure; however, safety data insufficient. Use Calvert formula based on renal function; monitor for toxicity and adjust as needed.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Paraplatin (carboplatin) dosing is based on renal function using Calvert formula to calculate AUC. Dose adjustments required for Cr Cl <60 m L/min. Administer IV infusion over 15-60 minutes. Hypersensitivity reactions may occur after multiple cycles; premedicate with antihistamines and corticosteroids if prior reaction. Monitor CBC weekly during treatment. Emetogenic potential: moderate-high; use antiemetic prophylaxis. Avoid concurrent nephrotoxic drugs. Myelosuppression (especially thrombocytopenia) is dose-limiting.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
This drug may lower your blood cell counts; report any signs of infection (fever, chills), easy bruising or bleeding, or unusual tiredness.,You may experience nausea or vomiting; take anti-nausea medications as prescribed.,Avoid live vaccines during treatment and for 6 months after.,Tell your doctor if you have had an allergic reaction to platinum-based drugs.,Use effective contraception during and for 6 months after treatment; do not breastfeed.,Drink plenty of fluids to stay hydrated unless otherwise instructed.,Report any hearing changes, ringing in ears, or numbness/tingling in hands or feet.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PARAPLATIN vs CLOLAR, answered by our medical review team.
PARAPLATIN is a Antineoplastic Agent that works by Carboplatin, a platinum-based alkylating agent, forms interstrand and intrastrand DNA cross-links by binding to DNA guanine bases, inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PARAPLATIN and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PARAPLATIN is: 360 mg/m2 IV every 3 weeks or area under the curve (AUC) 4-6 mg/m L/min IV every 3-4 weeks using Calvert formula.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PARAPLATIN and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PARAPLATIN is classified as Category C. Pregnancy Category D. First trimester: High risk of teratogenicity; embryotoxicity, fetal malformations (neural tube, skeletal, cardiovascular). Second and third trimesters: Risk o. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.